Jay Olson
Stock Analyst at Oppenheimer
(4.47)
# 391
Out of 4,435 analysts
179
Total ratings
50%
Success rate
21.22%
Average return
Main Sectors:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Maintains: Outperform | $18 | $8.40 | +114.29% | 5 | May 15, 2024 | |
| STRO Sutro Biopharma | Maintains: Outperform | $10 | $4.23 | +136.69% | 5 | May 15, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Outperform | $102 → $95 | $53.74 | +76.78% | 6 | May 10, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 | $15.10 | +25.83% | 11 | May 6, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $200 → $216 | $135.41 | +59.52% | 11 | May 2, 2024 | |
| BIIB Biogen | Maintains: Outperform | $270 | $224.94 | +20.03% | 19 | Apr 29, 2024 | |
| INCY Incyte | Maintains: Outperform | $92 → $84 | $57.79 | +45.35% | 8 | Apr 24, 2024 | |
| SAGE Sage Therapeutics | Maintains: Perform | $25 → $17 | $11.11 | +53.02% | 7 | Apr 18, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $43 → $45 | $38.33 | +17.40% | 6 | Apr 12, 2024 | |
| SKYE Skye Bioscience | Initiates: Outperform | $25 | $11.61 | +115.33% | 1 | Apr 12, 2024 | |
| QTTB Q32 Bio | Initiates: Outperform | $50 | $25.50 | +96.08% | 1 | Apr 11, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $72 → $75 | $37.57 | +99.63% | 3 | Apr 9, 2024 | |
| VKTX Viking Therapeutics | Maintains: Outperform | $116 → $138 | $62.26 | +121.65% | 7 | Mar 27, 2024 | |
| CGTX Cognition Therapeutics | Maintains: Outperform | $9 | $1.95 | +361.54% | 4 | Mar 27, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $320 → $375 | $236.16 | +58.79% | 7 | Mar 15, 2024 | |
| MRNS Marinus Pharmaceuticals | Maintains: Perform | $9 | $1.42 | +533.80% | 4 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 | $25.96 | +208.17% | 4 | Mar 7, 2024 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $1.39 | +1,698.56% | 1 | Mar 5, 2024 | |
| ETNB 89bio | Maintains: Perform | n/a | $7.90 | - | 5 | Mar 5, 2024 | |
| PRTA Prothena Corporation | Maintains: Outperform | $98 → $80 | $20.81 | +284.43% | 8 | Feb 20, 2024 | |
| AMGN Amgen | Reiterates: Outperform | $350 | $305.85 | +14.44% | 16 | Feb 1, 2024 | |
| BIVI BioVie | Maintains: Outperform | $12 → $5 | $0.46 | +997.69% | 4 | Nov 30, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Perform | $25 → $21 | $12.47 | +68.40% | 7 | Nov 22, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $80 → $70 | $21.38 | +227.41% | 7 | Nov 13, 2023 | |
| EXEL Exelixis | Maintains: Outperform | $25 → $29 | $21.69 | +33.70% | 3 | Aug 22, 2023 | |
| EDIT Editas Medicine | Reiterates: Perform | $12 | $5.20 | +130.77% | 5 | Aug 3, 2023 | |
| GLTO Galecto | Reiterates: Outperform | $12 | $0.61 | +1,873.68% | 2 | Aug 1, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $70 → $68 | $18.56 | +266.38% | 3 | Jun 6, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Outperform | $55 | $22.19 | +147.86% | 2 | May 8, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Perform | $5 → $3 | $1.27 | +136.22% | 2 | Mar 6, 2023 | |
| RLMD Relmada Therapeutics | Downgrades: Perform | n/a | $3.00 | - | 2 | Oct 13, 2022 | |
| MDWD MediWound | Maintains: Outperform | n/a | $16.31 | - | 1 | Mar 20, 2018 | |
| TXMD TherapeuticsMD | Upgrades: Outperform | n/a | $2.22 | - | 2 | Jul 11, 2017 |
Voyager Therapeutics
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $8.40
Upside: +114.29%
Sutro Biopharma
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $4.23
Upside: +136.69%
CRISPR Therapeutics AG
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $53.74
Upside: +76.78%
ACADIA Pharmaceuticals
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $15.10
Upside: +25.83%
Neurocrine Biosciences
May 2, 2024
Maintains: Outperform
Price Target: $200 → $216
Current: $135.41
Upside: +59.52%
Biogen
Apr 29, 2024
Maintains: Outperform
Price Target: $270
Current: $224.94
Upside: +20.03%
Incyte
Apr 24, 2024
Maintains: Outperform
Price Target: $92 → $84
Current: $57.79
Upside: +45.35%
Sage Therapeutics
Apr 18, 2024
Maintains: Perform
Price Target: $25 → $17
Current: $11.11
Upside: +53.02%
Revolution Medicines
Apr 12, 2024
Maintains: Outperform
Price Target: $43 → $45
Current: $38.33
Upside: +17.40%
Skye Bioscience
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $11.61
Upside: +115.33%
Q32 Bio
Apr 11, 2024
Initiates: Outperform
Price Target: $50
Current: $25.50
Upside: +96.08%
Ionis Pharmaceuticals
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $37.57
Upside: +99.63%
Viking Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $116 → $138
Current: $62.26
Upside: +121.65%
Cognition Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.95
Upside: +361.54%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $320 → $375
Current: $236.16
Upside: +58.79%
Marinus Pharmaceuticals
Mar 7, 2024
Maintains: Perform
Price Target: $9
Current: $1.42
Upside: +533.80%
Jasper Therapeutics
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $25.96
Upside: +208.17%
Immuneering
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $1.39
Upside: +1,698.56%
89bio
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $7.90
Upside: -
Prothena Corporation
Feb 20, 2024
Maintains: Outperform
Price Target: $98 → $80
Current: $20.81
Upside: +284.43%
Amgen
Feb 1, 2024
Reiterates: Outperform
Price Target: $350
Current: $305.85
Upside: +14.44%
BioVie
Nov 30, 2023
Maintains: Outperform
Price Target: $12 → $5
Current: $0.46
Upside: +997.69%
Enanta Pharmaceuticals
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $12.47
Upside: +68.40%
Intellia Therapeutics
Nov 13, 2023
Maintains: Outperform
Price Target: $80 → $70
Current: $21.38
Upside: +227.41%
Exelixis
Aug 22, 2023
Maintains: Outperform
Price Target: $25 → $29
Current: $21.69
Upside: +33.70%
Editas Medicine
Aug 3, 2023
Reiterates: Perform
Price Target: $12
Current: $5.20
Upside: +130.77%
Galecto
Aug 1, 2023
Reiterates: Outperform
Price Target: $12
Current: $0.61
Upside: +1,873.68%
Denali Therapeutics
Jun 6, 2023
Maintains: Outperform
Price Target: $70 → $68
Current: $18.56
Upside: +266.38%
Bicycle Therapeutics
May 8, 2023
Reiterates: Outperform
Price Target: $55
Current: $22.19
Upside: +147.86%
Nektar Therapeutics
Mar 6, 2023
Maintains: Perform
Price Target: $5 → $3
Current: $1.27
Upside: +136.22%
Relmada Therapeutics
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.00
Upside: -
MediWound
Mar 20, 2018
Maintains: Outperform
Price Target: n/a
Current: $16.31
Upside: -
TherapeuticsMD
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.22
Upside: -